compound 9 [Kumar et al., 2019]   Click here for help

GtoPdb Ligand ID: 10448

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Compound 9 is an example of a new chemotype (with a cyclic enaminone structural scaffold) for selective COX2 inhibitors (COXIBs) [1]. It is hoped that this new chemotype will be devoid of the side effects related to the sulfonamide/sulfonate group common in existing COXIB drugs, and thus lead the way to overcoming the adverse cardiovascular effects that have led to the withdrawl of some existing COXIBs from use in the clinic (rofecoxib and valdecoxib).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 3
Topological polar surface area 37.38
Molecular weight 263.07
XLogP 2.17
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(=O)N(c1ccc(cc1)Cl)C1=CC(=O)CCC1
Isomeric SMILES CC(=O)N(c1ccc(cc1)Cl)C1=CC(=O)CCC1
InChI InChI=1S/C14H14ClNO2/c1-10(17)16(12-7-5-11(15)6-8-12)13-3-2-4-14(18)9-13/h5-9H,2-4H2,1H3
InChI Key UOYMKJRPIIMBTR-UHFFFAOYSA-N
Immunopharmacology Comments
Compound 9 is a selective COX2 inhibitor [1]. Its anti-inflammatory activity is equal to/better than that of celecoxib and comparable to that of the non-selective COX inhibitor diclofenac. Compound 9 is non-ulcerogenic in rats and has a gastrointestinal safety profile better than indomethacin.